Summit Therapeutics Gets a Buy Rating from Canaccord Genuity


In a report released today, Arlinda Lee from Canaccord Genuity maintained a Buy rating on Summit Therapeutics (NASDAQ: SMMT), with a price target of $28. The company’s shares opened today at $13.37.

According to TipRanks.com, Lee is a 4-star analyst with an average return of 7.0% and a 47.4% success rate. Lee covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Aquinox Pharmaceuticals, and Zynerba Pharmaceuticals.

Currently, the analyst consensus on Summit Therapeutics is Strong Buy and the average price target is $28, representing a 109.4% upside.

In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $20 price target.

See today’s analyst top recommended stocks >>

Based on Summit Therapeutics’ latest earnings release for the quarter ending January 31, the company reported a quarterly GAAP net loss of $15.53 million. In comparison, last year the company had a GAAP net loss of $5.94 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Summit Therapeutics Plc is a holding company, which engages in the discovery, development, and commercialization of novel medicines. It focuses on the genetic disease duchenne muscular dystrophy, and the infectious disease clostridium difficile infection.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts